THE BEST SIDE OF TRASTUZUMAB DERUXTECAN COPYRIGHT

One of the most underneath-investigated “driving forces” associated with trastuzumab resistance is PTEN. Nagata et al. (2004) reported that the lack of PTEN was noticed in 36% of HER2-beneficial Principal breast tumor specimens from individuals with phase IV condition. Also, they also showed that people with PTEN-deficient tumors had remarkably